u/bpc_sceptic

Small correction: the trial was 5 weeks, not 20. Does not change your point but people will quote it.

Cosigning the evidence standard. Receipts make the community.

Disagree. What you are describing is consistent with CagriSema, not with what you concluded.

sequence and naming claims need the actual sequence

Tracking number removed. It identifies both ends of a shipment.

This is correct. The co-agonism is real.

This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.

order date, product, and what was tested. that is the template.

This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.

My Janoshik result matched the vendor COA exactly, which is rare. BCH deserves that note in the directory.

the co-agonism question is real and interesting

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

Tested 4 batches from GL Biochem over 54 weeks. Spread was 94.2% to 97.9, mostly 94.2. Consistent vendor.

Correct. The batch number is load-bearing information, not optional.

Batch number?

Disagree on that part. 99.2% and 99.3% on the same vial is normal.

TFC three times. First two perfect, third arrived with a gel pack failure. Powder tested 97.4% anyway, so no harm done.

the co-agonism question is real and interesting

Adding to this: REDEFINE is doing more work than the comment implies.

Not convinced. The evidence does not support that reading.

That is net peptide content, not purity. Different number, different meaning.

The confident tone is doing a lot of work that the evidence is not.